Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Martí Carvajal, Arturo J ^a   Agreda Pérez, Luis H ^b   Solà, Ivan ^c   Simancas Racines, Daniel ^a  

^a School of Engineering Sciences and Industry   (Ecuador)

^b Hospital Dr Adolfo Prince Lara   (Venezuela)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN A; RECOMBINANT PROTEIN;

ANEMIA; BLOOD PRESSURE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FATIGUE; GLOBAL ASSESSMENT OF FUNCTIONING; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL BIAS; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL ANALOG SCALE; BLOOD; META ANALYSIS; METABOLISM;

ANEMIA; ARTHRITIS, RHEUMATOID; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBIN A; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 84875492718     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000332.pub3     Document Type: Review

References (133)

1. Nordström D, Lindroth Y, Marsal L, Hafstrom I, Henrich C, Rantapaa-Dahlqvist S, et al.Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatology International 1997;17(2):67-73. [PUBMED: 9266623]
2. Peeters HR, Jongen-Lavrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJ. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatology International 1999;18(5-6):201-6. [PUBMED: 10399796]
3. Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomized placebo controlled double blind 52 weeks clinical trial. Annals of the Rheumatic Diseases 1996;55(10):739-44. [PUBMED: 8984939]
4. Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris ER, Schnitzer TJ, et al.Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. The American Journal of Medicine 1990;89(2):161-8. [PUBMED: 2200263]
5. Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Annals of Hematology 2005;84(3):159-66. [PUBMED: 15565327]
6. Birgegard G, Gudbjronsson B, Hallgren R, Wide L. Anemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin. Contributions to Nephrology 1991;88:295-303; discussion 304-5. [PUBMED: 2040192]
7. Dyjas R, Bulanowski M, Ficek R, Witkowicz J, Chudek J, Wiecek A. [Influence of recombinant human erythropoietin (rHuEPO) on plasma levels of selected hormones in females with rheumatoid arthritis] [Wplyw leczenia niedokrwistosci za pomoca ludzkiej erytropoetyny uzyskanej metodt rekombinacji genetycznej (rHuEPO) na stezenie w osoczu wybranych hormonow u kobiet chorych na reumatoidalne zapalenie stawow.]. Polskie Archiwum Medycyny Wewnetrznej 2005;114(2):731-7. [PUBMED: 16808310]
8. Fantini F, Gattinara M, Gerloni V, Bergomi P, Cirla E. Severe anemia associated with active systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoietin: a pilot study. Arthritis and Rheumatism 1992; Vol. 35, issue 6:724-6. [PUBMED: 1599527]
9. Goodnough LT, Marcus RE. The erythropoietic response to erythropoietin in patients with rheumatoid arthritis. The Journal of Laboratory and Clinical Medicine 1997;130(4):381-6. [PUBMED: 9358076]
10. Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. The Journal of Rheumatology 2001;28(11):2430-6. [PUBMED: 11708414]
11. Kato Y, Takagi C, Tanaka J, Masaki Y, Furuya H. Effect of daily subcutaneous administration of recombinant erythropoietin on chronic anemia in rheumatoid arthritis. Internal Medicine (Tokyo, Japan) 1994;33(4):193-7. [PUBMED: 8069012]
12. Krantz SB. Erythropoietin and the anaemia of chronic disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1995;10 Suppl 2:10-7. [PUBMED: 7644100]
13. Matsuda S, Kondo M, Mashima T, Hoshino S, Shinohara N, Sumida S. Recombinant human erythropoietin therapy for autologous blood donation in rheumatoid arthritis patients undergoing total hip or knee arthroplasty. Orthopedics 2001;24(1):41-4. [PUBMED: 11199350]
14. Means RT Jr, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, et al.Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis and Rheumatism 1989;32(5):638-42. [PUBMED: 2719734]
15. Mercuriali F. Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. Seminars in Hematology 1996;33(2 Suppl 2):18-20; discussion 21. [PUBMED: 8723576]
16. Mercuriali F, Inghilleri G, Biffi E, Colotti MT, Vinci A, Sinigaglia L, et al.Comparison between intravenous and subcutaneous recombinant human erythropoietin (Epoetin alfa) administration in presurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Vox Sanguinis 1997;72(2):93-100. [PUBMED: 9088076]
17. Mercuriali F, Gualtieri G, Biffi E, Inghilleri G, Colotti M, Vinci A, et al.Intravenous vs subcutaneous erythropoietin for autologous blood donation in anemic rheumatoid arthritis patients. Transfusion Supplement. 1994; Vol. 34.
18. Mercuriali F, Gualtieri G, Inghilleri G, Biffi E, Vinci A, Colotti M, et al.Erythropoietin and autologous blood donation in surgical rheumatoid arthritis patients with anemia. Transfusion Abstract. Florida, 1993; Vol. 33, issue 28.
19. Murphy EA, Bell AL, Wojtulewski J, Brzeski M, Madhok R, Capell HA. Study of erythropoietin in treatment of anaemia in patients with rheumatoid arthritis. BMJ 1994;309(6965):1337-8. [PUBMED: 7866082]
20. Pettersson T, Rosenlof K, Friman C, Mickos A, Teppo A M, Fyhrquist F. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation. Scandinavian Journal of Rheumatology 1993;22(4):188-93. [MEDLINE: 8356412]
21. Saikawa I, Hotokebuchi T, Arita C, Inaba S, Shuto T, Tsutsui H, et al.Autologous blood transfusion with recombinant erythropoietin treatment. 22 arthroplasties for rheumatoid arthritis. Acta Orthopaedica Scandinavica 1994;65(1):15-9. [PUBMED: 8154276]
22. Salvarani C, Lasagni D, Casali B, Macchioni P, Boiardi L, Rossi F, et al.Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease. The Journal of Rheumatology 1991;18(8):1168-71. [PUBMED: 1941817]
23. Swaak AJ, Nieuwenhuizen C, Vreugdenhil G. Recombinant human erythropoietin (r-hu-EPO) treatment in patients with rheumatoid arthritis and anaemia of chronic disease (ACD). Clinical and Experimental Rheumatology 1994; Vol. 12, issue 5:577. [PUBMED: 7842542]
24. Takashina N, Kondo H, Kashiwazaki S. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. The Journal of Rheumatology 1990;17(7):885-7. [PUBMED: 2213753]
25. Tauchi T, Ohyashiki JH, Fujieda H, Lin KY, Ohyashiki K, Toyama K. Correction of anaemia in rheumatoid arthritis by recombinant human erythropoietin. British Journal of Rheumatology 1990; Vol. 29, issue 3:235-6. [PUBMED: 2357513]
26. Vreugdenhil G, Swaak AJ. The role of erythropoietin in the anaemia of chronic disease in rheumatoid arthritis. Clinical Rheumatology 1990;9(1):22-7. [PUBMED: 2185909]
27. Vreugdenhil G, Manger B, Nieuwenhuizen C, Feelders RA, van Eijk HG, Swaak AJ. Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Annals of Hematology 1992;65(6):265-8. [PUBMED: 1457588]
28. Agarwal N, Prchal JT. Anemia of chronic disease (anemia of inflammation). Acta Haematologica 2009;122:103-8. [PUBMED: 19907147]
29. Al-Ghamdi A, Attar SM. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Annals of Saudí Medicine 2009;29:189-93. [PUBMED: 19448378]
30. Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, et al.Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. The Journal of Rheumatology 2011; Vol. 38, issue 8:1745-50. [PUBMED: 21807796]
31. Andrews NC, Schmidt PJ. Iron homeostasis. Annual Review of Physiology 2007;69:69-85. [PUBMED: 17014365]
32. Andrews NC. Forging a field: the golden age of iron biology. Blood 2008;112:219-30. [PUBMED: 18606887]
33. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315-24. [PUBMED: 3358796]
34. Baer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. British Journal of Haematology 1987;66:599-64. [PUBMED: 3663512]
35. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al.GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
36. Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, et al.Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Annals of the Rheumatic Diseases Jul 6. [Epub ahead of print]. [PUBMED: 22772326]
37. Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al.Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40. [PUBMED: 22511692]
38. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al.Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24. [PUBMED: 18314434 ]
39. Bingham CO 3rd, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, et al.Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. The Journal of Rheumatology 2011; Vol. 38, issue 8:1751-8. [PUBMED: 21807797]
40. Blumenauer BBTB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al.Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785]
41. Blumenauer BBTB, Cranney A, Burls A, Coyle D, Hochberg MC, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004525]
42. Capocasale RJ, Makropoulos DA, Achuthanandam R, Stowell N, Quinn J, Rafferty PA, et al.Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice. Cytometry A 2008;73:148-59. [PUBMED: 18205195]
43. Cartwright GE. The anemia of chronic disorders. Seminars in Hematology 1966;3:351-75. [PUBMED: 5341723]
44. Cases A. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs of Today (Barc) 2003;39:477-95. [PUBMED: 12973399]
45. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007;8:39. [PUBMED: 18039365]
46. Coussons PJ, Baig S, Fanutti C, Grant R. Novel tissue remodelling roles for human recombinant erythropoietin. Biochemical Society Transactions 2005;33 (Pt 5):1129-30. [PUBMED: 16246063]
47. Cronstein BN. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2007;65 (Suppl 1):11-5. [PUBMED: 17708739 ]
48. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010;49:15-24. [PUBMED: 19854855]
49. Demirag MD, Haznedaroglu S, Sancak B, Konca C, Gulbahar O, Ozturk MA, et al.Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Internal Medicine 2009;48:421-6. [PUBMED: 19293540]
50. Food, Drug Administration. EPOGEN (epoetin alfa) solution. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9169 [Accessed January 29, 2010].
51. Food, Drug Administration. Erythropoiesis Stimulating Agents: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110251.htm March 07, 2008 (Accessed Jan 29, 2010).
52. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmunity Reviews 2009;8:538-42. [PUBMED: 19189867]
53. Furst DE, Chang H, Greenberg JD, Ranganath VK, Reed G, Ozturk ZE, et al.Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clinical and Experimental Rheumatology 2009;27:560-6. [PUBMED: 19772785]
54. Gabriel SE, Normand SL. Getting the methods right - the foundation of patient-centered outcomes research. The New England Journal of Medicine 2012 Jul 25 [Epub ahead of print]. [PUBMED: 22830434]
55. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Seminars in Hematology 2009;46:387-93. [PUBMED: 19786207]
56. Glaspy 2009. Erythropoietin in cancer patients. Annual Review of Medicine 2009;60:181-92. [PUBMED: 18980468]
57. Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows 2008.
58. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. European Journal of Radiology 1998;27 (Suppl 1):18-24. [PUBMED: 9652497]
59. Gudbjörnsson B, Hällgren R, Wide L, Birgegård G. Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Annals of Rheumatic Diseases 1992;51:747-52. [PUBMED: 1616357]
60. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
61. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al.GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
62. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al.GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
63. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al.GRADE guidelines: 5. Rating the quality of evidence--publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
64. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
65. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
66. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.GRADE guidelines: 8. Rating the quality of evidence--indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
67. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al.GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
68. Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, et al.Association of anemia and physical disability among patients with rheumatoid arthritis. Journal of Rheumatology 2007;34:2177-82. [PUBMED: 17937474]
69. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. Journal of the National Cancer Institute 2009;101:1633-41. [PUBMED: 19903808 ]
70. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. [PUBMED: 12958120]
71. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.5 [updated September 29th, 2009]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Hochberg MC, Arnold CM, Hogans BB, Spivak JL. Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia. Arthritis and Rheumatism 1988;31:1318-21. [PUBMED: 3178910]
73. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Current Medical Research and Opinion 2008;24:469-80. [PUBMED: 18179735 ]
74. Hopewell S, Clarke M, Higgins JPT (editors). Core reporting of outcomes in effectiveness trials. Cochrane Methods. Cochrane Database of Systematic Reviews 2010; Vol. Suppl 1:1-29. [: ISSN 2044-4702]
75. Ibbotson T, Goa KL. Darbepoetin alfa. Drugs 2001;61:2097-104. [PUBMED: 11735636]
76. Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annual Review of Pathology 2009;4:417-34. [PUBMED: 18954286]
77. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al.Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. [PUBMED: 15545678]
78. Ioannidis JP. The art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
79. Jaworski J, Maslinski W, Pazdur J, Sliwinska-Stanczyk P, Kaminska-Tchorzewska E, Jung L, et al.Decreased expression of integrins by hematopoietic cells in patients with rheumatoid arthritis and anemia: relationship with bone marrow cytokine levels. Journal of Investigational Allergology & Clinical Immunology 2008;18:17-21. [PUBMED: 18361097]
80. Jayaranee S, Sthaneshwar P, Sokkalingam S. Serum prohepcidin concentrations in rheumatoid arthritis. Pathology 2009;41:178-82. [PUBMED: 18972320]
81. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al.The impact of outcome reporting bias in randomized controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [PUBMED: 20156912]
82. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al.Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. Journal of Rheumatology 2007;34:1174-7. [PUBMED: 17477482]
83. Kishimoto T. Interleukin-6: from basic science to medicine--40 years in immunology. Annual Review of Immunology 2005;23:1-21. [PUBMED: 15771564 ]
84. Krantz SB, Sawyer ST, Sawada K, Wolfe F, Bocagno J. Erythropoietin: receptors and clinical use in rheumatoid arthritis. International Journal of Cell Cloning 1990;8 (Suppl 1):181-95.
85. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11. [PUBMED: 11567728]
86. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annual Review of Pathology 2009;4:489-515. [PUBMED: 19400694]
87. Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. European Journal of Clinical Investigation 2005;35 (Suppl 3):32-5. [PUBMED: 16281956]
88. Masson C. Rheumatoid anemia. Joint, Bone, Spine 2011;78(2):131-7. [PUBMED: 20851655]
89. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007277.pub2]
90. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine 2011;365(23):2205-19. [PUBMED: 22150039]
91. Means RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 1995;13:32-7. [PUBMED: 7719246]
92. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005121.pub3]
93. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology 2007;21:885-906. [PUBMED: 17870034]
94. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al.CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. BMJ 2010;340:c869. [PUBMED: 20332511]
95. Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Seminars in Arthritis and Rheumatism 2009;39:132-43. [PUBMED: 19022481]
96. Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World Journal of Gastroenterology 2009;15:4617-26. [PUBMED: 19787824 ]
97. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2]
98. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140:795-801. [PUBMED: 15148066]
99. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematologica 2003;122:78-86. [PUBMED: 19907144 ]
100. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al.IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation 2004;113:1271-6. [PUBMED: 15124018]
101. Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. Journal of Rheumatology 2008;35:380-6. [PUBMED: 18260177]
102. Papadaki HA, Kritikos HD, Gemetzi C, Koutala H, Marsh JC, Boumpas DT, et al.Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002;99:1610-9. [PUBMED: 11861275]
103. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis and rheumatism 1990;33(4):477-84. [PUBMED: 2109613]
104. Patient-Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: "Our questions, our decisions: Standards for patient-centered outcomes research". http://www.pcori.org/assets/Preliminary-Draft-Methodology-Report.pdf (accessed 27 July 2012):1-61.
105. Pettersson T, Rosenlöf K, Friman C, Mickos A, Teppo AM, Fyhrquist F. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation. Scandinavian Journal of Rheumatology 193;22:188-93. [PUBMED: 8356412]
106. Pettersson T, Rosenlöf K, Laitinen E, Tenhunen R. Effect of exogenous erythropoietin on haem synthesis in anaemic patients with rheumatoid arthritis. British Journal of Rheumatology 1994;33:526-9. [PUBMED: 8205399]
107. Porta M. A Dictionary of Epidemiology. New York: Oxford University Press, 2008. [: ISBN 978-0-19-531449-6]
108. Raj DS. Role of interleukin-6 in the anemia of chronic disease. Seminars in Arthritis and Rheumatism 2009;38:382-8. [PUBMED: 18336871]
109. The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011.
110. Roy CN, Andrews NC. Anemia of inflammation: the hepcidin link. Current Opinion in Hematology 2005;12:105-11. [PUBMED: 15725899]
111. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ESC, et al.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD007649.pub2]
112. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al.Anti-hepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010;115(17):3616-24. [PUBMED: 20053755]
113. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al.Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2]
114. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341]
115. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD008331.pub2]
116. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al.Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008794.pub2]
117. Smith MA, Knight SM, Maddison PJ, Smith JG. Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages. Annals of the Rheumatic Diseases 1992;51:753-7. [PUBMED: 1616358]
118. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al.Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 2011;343:d4002. [PUBMED: 21784880]
119. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al.Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-86. [PUBMED: 19293425 ]
120. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38. [PUBMED: 18039364]
121. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Annals of the Rheumatic Diseases 2003;62:722-7. [PUBMED: 12860726]
122. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents--time for a reevaluation. New England Journal of Medicine 2010;362:189-92. [PUBMED: 20054037]
123. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nature Clinical Practice. Nephrology 2008;4(1):47-57. [PUBMED: 18094727]
124. Vreugdenhil G, Löwenberg B, Van Eijk HG, Swaak AJ. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. European Journal of Clinical Investigation 1992;22:488-93. [PUBMED: 1516597]
125. Vreugdenhil G, Manger B, Nieuwenhuizen C, Feelders RA, van Eijk HG, Swaak AJ. Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Annals of Hematology 1992;65:265-8. [PUBMED: 1457588]
126. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Review 2002;16:87-96. [PUBMED: 12127952]
127. Weiss G. Iron metabolism in the anemia of chronic disease. Biochimica et Biophysica Acta 2009;1790:682-93. [PUBMED: 18786614]
128. de Benoist B, McLean E, Egli I, Cogswell M, editors. Worldwide prevalence of anaemia 1993-2005 : WHO global database on anaemia. Geneva: World Health Organization, 2008. [: ISBN 978 92 4 159665 7]
129. Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. American Journal of Medicine 2004;116(Suppl 7A):50-7. [PUBMED: 15050886 ]
130. Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer 2003;98:2410-9. [PUBMED: 14635076]
131. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Practice & Reserach. Clinical Rheumatology 2007;21:907-27. [PUBMED: 17870035]
132. Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009:207-14. [PUBMED: 20008200]
133. Zhu Y, Ye D, Huang Z. The correlation of cytokines TNF alpha, IFN-gamma, Epo with anemia in rheumatoid arthritis. Zhonghua Xueyexue Zazhi 2000;21:587-90. [PUBMED: 11225250 ]